Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Ionis and its RNAi drug Tegsedi got a head start with England's NHS, putting the pressure on Alnylam's rival med Onpattro. But now, the country's drug cost watchdog has changed its mind and backed the Alnylam drug, too.